Arrowstreet Capital Limited Partnership Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Arrowstreet Capital Limited Partnership increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 127.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,541,181 shares of the biopharmaceutical company’s stock after purchasing an additional 1,425,674 shares during the quarter. Arrowstreet Capital Limited Partnership owned 2.06% of Halozyme Therapeutics worth $132,192,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of HALO. Quantbot Technologies LP grew its holdings in shares of Halozyme Therapeutics by 78.5% in the second quarter. Quantbot Technologies LP now owns 15,872 shares of the biopharmaceutical company’s stock worth $826,000 after acquiring an additional 6,981 shares during the period. OMERS ADMINISTRATION Corp bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $770,000. Schroder Investment Management Group grew its stake in shares of Halozyme Therapeutics by 1.8% during the 2nd quarter. Schroder Investment Management Group now owns 246,975 shares of the biopharmaceutical company’s stock valued at $12,848,000 after purchasing an additional 4,468 shares during the period. Mackenzie Financial Corp increased its position in shares of Halozyme Therapeutics by 38.3% during the 2nd quarter. Mackenzie Financial Corp now owns 118,426 shares of the biopharmaceutical company’s stock valued at $6,161,000 after purchasing an additional 32,817 shares during the last quarter. Finally, Virtus Investment Advisers LLC lifted its stake in shares of Halozyme Therapeutics by 8.6% in the 2nd quarter. Virtus Investment Advisers LLC now owns 8,148 shares of the biopharmaceutical company’s stock worth $424,000 after purchasing an additional 643 shares during the period. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $66.54 on Wednesday. The company has a market capitalization of $7.82 billion, a price-to-earnings ratio of 15.23, a PEG ratio of 0.35 and a beta of 1.18. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The stock’s 50-day simple moving average is $68.83 and its 200-day simple moving average is $64.20. Halozyme Therapeutics, Inc. has a 52 week low of $46.26 and a 52 week high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. During the same quarter last year, the company earned $1.27 EPS. The firm’s quarterly revenue was up 22.1% on a year-over-year basis. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HALO has been the subject of a number of research reports. Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price for the company in a report on Tuesday, October 14th. Morgan Stanley cut their price objective on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. The Goldman Sachs Group upped their price objective on Halozyme Therapeutics from $54.00 to $56.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 18th. Benchmark lifted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.10.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 2,227 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $77.95, for a total transaction of $173,594.65. Following the completion of the transaction, the chief financial officer owned 22,079 shares in the company, valued at $1,721,058.05. This trade represents a 9.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Helen Torley sold 16,569 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $68.92, for a total value of $1,141,935.48. Following the completion of the sale, the chief executive officer directly owned 708,719 shares in the company, valued at approximately $48,844,913.48. The trade was a 2.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 103,625 shares of company stock worth $7,446,727. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.